MA39090B2 - Anti-ccl17 antibodies - Google Patents

Anti-ccl17 antibodies

Info

Publication number
MA39090B2
MA39090B2 MA39090A MA39090A MA39090B2 MA 39090 B2 MA39090 B2 MA 39090B2 MA 39090 A MA39090 A MA 39090A MA 39090 A MA39090 A MA 39090A MA 39090 B2 MA39090 B2 MA 39090B2
Authority
MA
Morocco
Prior art keywords
antibodies
ccl17
ccl17 antibodies
polynucleotides
fragments
Prior art date
Application number
MA39090A
Other languages
French (fr)
Other versions
MA39090A1 (en
Inventor
Ken Boakye
Vecchio Alfred Del
John Kehoe
Eilyn Lacy
Lynne Murray
Mary Ryan
Sandra Santulli-Marotto
John Wheeler
Brian Whitaker
Alexey Teplyakov
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of MA39090A1 publication Critical patent/MA39090A1/en
Publication of MA39090B2 publication Critical patent/MA39090B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des anticorps se liant spécifiquement à ccl17, des polynucléotides codant ces anticorps ou fragments, et des méthodes de préparation et d'utilisation desdits anticorps et polynucléotides.The present invention relates to antibodies specifically binding to ccl17, polynucleotides encoding such antibodies or fragments, and methods of preparing and using said antibodies and polynucleotides.

MA39090A 2013-11-06 2014-11-06 Anti-ccl17 antibodies MA39090B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361900596P 2013-11-06 2013-11-06
PCT/US2014/064302 WO2015069865A1 (en) 2013-11-06 2014-11-06 Anti-ccl17 antibodies

Publications (2)

Publication Number Publication Date
MA39090A1 MA39090A1 (en) 2018-03-30
MA39090B2 true MA39090B2 (en) 2021-10-29

Family

ID=53007215

Family Applications (1)

Application Number Title Priority Date Filing Date
MA39090A MA39090B2 (en) 2013-11-06 2014-11-06 Anti-ccl17 antibodies

Country Status (33)

Country Link
US (4) US9944697B2 (en)
EP (2) EP3065774B1 (en)
JP (1) JP6556742B2 (en)
KR (1) KR102331054B1 (en)
CN (1) CN105722531B (en)
AU (1) AU2014346770B2 (en)
BR (1) BR112016010071A2 (en)
CA (1) CA2929166C (en)
CL (1) CL2016001081A1 (en)
CR (1) CR20160187A (en)
CY (1) CY1124445T1 (en)
DK (1) DK3065774T3 (en)
DO (1) DOP2016000105A (en)
EA (1) EA034655B1 (en)
ES (1) ES2884255T3 (en)
HR (1) HRP20211234T1 (en)
HU (1) HUE058272T2 (en)
IL (1) IL245488B (en)
LT (1) LT3065774T (en)
MA (1) MA39090B2 (en)
MX (1) MX2016005982A (en)
MY (1) MY192757A (en)
NZ (2) NZ758354A (en)
PE (1) PE20160856A1 (en)
PH (1) PH12016500826B1 (en)
PL (1) PL3065774T3 (en)
PT (1) PT3065774T (en)
RS (1) RS62373B1 (en)
SG (1) SG11201603231XA (en)
SI (1) SI3065774T1 (en)
SM (1) SMT202100473T1 (en)
UA (1) UA119973C2 (en)
WO (1) WO2015069865A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3065774T3 (en) * 2013-11-06 2021-12-13 Janssen Biotech, Inc Anti-ccl17 antibodies
EP3363814A4 (en) * 2015-10-14 2019-09-25 Nippon Zenyaku Kogyo Co., Ltd. Anti-canine tarc antibody used for treatment and diagnosis of canine atopic dermatitis
WO2017079369A2 (en) * 2015-11-03 2017-05-11 Glaxosmithkline Llc Novel antibodies
DK3380522T5 (en) 2015-11-25 2024-09-30 Visterra Inc ANTIBODY MOLECULES TO APRIL AND USES THEREOF
CN108250290B (en) 2018-02-23 2024-03-12 上海捌加壹医药科技有限公司 N-terminal recombinant protein of CCR4 and its uses
JP6979149B1 (en) * 2020-07-10 2021-12-08 積水メディカル株式会社 A composition containing TARC and a method for improving the storage stability of TARC.
WO2022009974A1 (en) * 2020-07-10 2022-01-13 積水メディカル株式会社 Composition containing tarc, and method for improving storage stability of tarc
WO2024127277A1 (en) * 2022-12-16 2024-06-20 Glaxosmithkline Intellectual Property Development Limited Method of treating pain with an anti-ccl17 antibody

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US226A (en) 1837-06-03 Samuel goss
US7709A (en) 1850-10-08 Chas S Gaylord Improved spring-grapple
US4683985A (en) 1985-01-04 1987-08-04 Dresser Industries, Inc. Lubrication system for a vertical gear unit
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
WO1988001649A1 (en) 1986-09-02 1988-03-10 Genex Corporation Single polypeptide chain binding molecules
US5869620A (en) 1986-09-02 1999-02-09 Enzon, Inc. Multivalent antigen-binding proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
ATE255131T1 (en) 1991-06-14 2003-12-15 Genentech Inc HUMANIZED HEREGULIN ANTIBODIES
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
PT1696031E (en) 1991-12-02 2010-06-25 Medical Res Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
JP3720353B2 (en) 1992-12-04 2005-11-24 メディカル リサーチ カウンシル Multivalent and multispecific binding proteins, their production and use
WO1995015388A1 (en) 1993-12-03 1995-06-08 Medical Research Council Recombinant binding proteins and peptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
WO1997014719A1 (en) 1995-10-16 1997-04-24 Unilever N.V. A bifunctional or bivalent antibody fragment analogue
WO1997029192A1 (en) 1996-02-12 1997-08-14 Schering Corporation Mammalian dendritic cell chemokine reagents
DE19819846B4 (en) 1998-05-05 2016-11-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Multivalent antibody constructs
US6818749B1 (en) 1998-10-31 2004-11-16 The United States Of America As Represented By The Department Of Health And Human Services Variants of humanized anti carcinoma monoclonal antibody cc49
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7413031B2 (en) 2000-07-18 2008-08-19 The Charles Machine Works, Inc. Apparatus and method for maintaining control of a drilling machine
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
IL155977A0 (en) 2000-11-30 2003-12-23 Medarex Inc Transgenic transchromosomal rodents for making human antibodies
MXPA05000511A (en) 2001-07-12 2005-09-30 Jefferson Foote Super humanized antibodies.
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
WO2004111233A1 (en) 2003-06-11 2004-12-23 Chugai Seiyaku Kabushiki Kaisha Process for producing antibody
CN101198698B (en) 2005-03-31 2014-03-19 中外制药株式会社 Process for production of polypeptide by regulation of assembly
WO2007110205A2 (en) 2006-03-24 2007-10-04 Merck Patent Gmbh Engineered heterodimeric protein domains
WO2007147901A1 (en) 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
CN104497143B (en) 2007-03-29 2020-08-25 健玛保 Bispecific antibodies and methods of making the same
JP4341704B2 (en) 2007-07-12 2009-10-07 トヨタ自動車株式会社 Hybrid vehicle and control method of hybrid vehicle
GB0718167D0 (en) 2007-09-18 2007-10-31 Cancer Rec Tech Ltd Cancer marker and therapeutic target
US8748356B2 (en) 2007-10-19 2014-06-10 Janssen Biotech, Inc. Methods for use in human-adapting monoclonal antibodies
JP2011507519A (en) 2007-12-19 2011-03-10 セントコア・オーソ・バイオテツク・インコーポレーテツド Design and generation of human de novo pIX phage display library via fusion to pIX or pVII, vectors, antibodies, and methods
EP3663318A1 (en) 2008-01-07 2020-06-10 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
ES2456296T3 (en) 2008-03-27 2014-04-21 Zymogenetics, Inc. Compositions and procedures for inhibiting PDGFR beta and VEGF-A
JP5646457B2 (en) 2008-04-29 2014-12-24 アッヴィ・インコーポレイテッド Dual variable domain immunoglobulins and uses thereof
JP2012505654A (en) 2008-10-14 2012-03-08 ヤンセン バイオテツク，インコーポレーテツド Methods for humanizing and affinity maturating antibodies
AU2010245011B2 (en) 2009-04-27 2015-09-03 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
GB201005063D0 (en) 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
EP2496600A1 (en) * 2009-11-04 2012-09-12 Fabrus LLC Methods for affinity maturation-based antibody optimization
SI2506871T1 (en) 2009-11-30 2016-12-30 Janssen Biotech, Inc. ANTIBODY Fc MUTANTS WITH ABLATED EFFECTOR FUNCTIONS
US20110206672A1 (en) 2010-02-25 2011-08-25 Melvyn Little Antigen-Binding Molecule And Uses Thereof
JP6040148B2 (en) 2010-04-20 2016-12-07 ゲンマブ エー／エス Heterodimeric antibody Fc-containing protein and production method thereof
EP2569337A1 (en) 2010-05-14 2013-03-20 Rinat Neuroscience Corp. Heterodimeric proteins and methods for producing and purifying them
EP2420253A1 (en) 2010-08-20 2012-02-22 Leadartis, S.L. Engineering multifunctional and multivalent molecules with collagen XV trimerization domain
AR082518A1 (en) * 2010-08-25 2012-12-12 Hoffmann La Roche ANTIBODIES AGAINST IL-18R1 AND USES OF THE SAME
EP2621950A4 (en) 2010-09-27 2015-09-02 Janssen Biotech Inc Antibodies binding human collagen ii
CA2812392A1 (en) * 2010-09-27 2012-04-12 Janssen Biotech, Inc. Macaca fascicularis ccl17
PL2635607T3 (en) 2010-11-05 2020-05-18 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the fc domain
KR101962483B1 (en) * 2010-11-17 2019-03-29 추가이 세이야쿠 가부시키가이샤 Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor VIII
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
US20130171659A1 (en) * 2011-12-28 2013-07-04 Abbott Japan Co., Ltd. Methods of prognosis and diagnosis of rheumatoid arthritis
PL3065774T3 (en) * 2013-11-06 2021-12-13 Janssen Biotech, Inc Anti-ccl17 antibodies

Also Published As

Publication number Publication date
EA201690942A1 (en) 2016-09-30
EP3065774A1 (en) 2016-09-14
US20150125458A1 (en) 2015-05-07
US11414484B2 (en) 2022-08-16
EP3065774B1 (en) 2021-05-26
HRP20211234T1 (en) 2021-11-26
PL3065774T3 (en) 2021-12-13
HUE058272T2 (en) 2022-07-28
NZ758354A (en) 2022-09-30
SG11201603231XA (en) 2016-05-30
LT3065774T (en) 2021-09-10
AU2014346770B2 (en) 2020-05-21
US20220348647A1 (en) 2022-11-03
SMT202100473T1 (en) 2021-09-14
BR112016010071A2 (en) 2017-12-05
JP2016537024A (en) 2016-12-01
PT3065774T (en) 2021-08-31
EA034655B1 (en) 2020-03-03
SI3065774T1 (en) 2021-11-30
PH12016500826B1 (en) 2021-09-10
CL2016001081A1 (en) 2016-10-21
KR20160077198A (en) 2016-07-01
NZ719506A (en) 2022-09-30
IL245488A0 (en) 2016-06-30
WO2015069865A1 (en) 2015-05-14
US20210017267A1 (en) 2021-01-21
CN105722531A (en) 2016-06-29
PH12016500826A1 (en) 2016-06-13
MA39090A1 (en) 2018-03-30
US9944697B2 (en) 2018-04-17
IL245488B (en) 2020-03-31
JP6556742B2 (en) 2019-08-07
CR20160187A (en) 2016-08-04
CN105722531B (en) 2020-03-06
KR102331054B1 (en) 2021-11-24
CY1124445T1 (en) 2022-07-22
CA2929166C (en) 2023-08-22
RS62373B1 (en) 2021-10-29
DOP2016000105A (en) 2016-10-31
EP3466445A1 (en) 2019-04-10
MX2016005982A (en) 2016-08-11
PE20160856A1 (en) 2016-09-03
CA2929166A1 (en) 2015-05-14
US10829549B2 (en) 2020-11-10
DK3065774T3 (en) 2021-08-23
ES2884255T3 (en) 2021-12-10
MY192757A (en) 2022-09-07
UA119973C2 (en) 2019-09-10
EP3065774A4 (en) 2017-06-21
US20180171007A1 (en) 2018-06-21

Similar Documents

Publication Publication Date Title
MA43186B1 (en) Antibodies specifically binding to pd-1 and uses thereof
MA41669A1 (en) Antibodies binding to tau
MA41670A1 (en) Antibodies binding to tau
MA39090A1 (en) Anti-ccl17 Antibody
MA47664A1 (en) Anti-c10orf54 antibodies and their uses
MA43018B1 (en) Anti-pd1 antibodies and methods of use
MA43187A (en) SUBCUTANEOUS ANTI-CD38 ANTIBODY FORMULATIONS AND THEIR USES
UA111818C2 (en) ANTIBODY AGAINST CSF-1R
UA110470C2 (en) Antidote of anticoagulant
MA39095A1 (en) Anti-cd33 antibodies and immunoconjugates
WO2014160160A3 (en) Antibody drug conjugates and corresponding antibodies
MY209528A (en) Anti-il-33 antibodies and uses thereof
MA37538A2 (en) Anti-Ly6 antibodies and immunoconjugates and methods of use
WO2014059442A3 (en) Antibody based reagents that specifically recognize toxic oligomeric forms of tau
BR112015031073A2 (en) bicyclic bromodomain inhibitors
EA201491811A1 (en) ANTI-LgR5 ANTIBODIES AND IMMUNOCONJUGATES
EA201491496A1 (en) HSP90 C-END DOMAIN INHIBITORS
MX2018015274A (en) Anti-cd98 antibodies and antibody drug conjugates.
MX2018015268A (en) Anti-cd98 antibodies and antibody drug conjugates.
MA44665B1 (en) NOVEL ANTI-SIRPA ANTIBODIES AND THEIR THERAPEUTIC USES
MA49289A (en) ANTIBODIES BINDING TO STEAP-1
EA201890434A1 (en) ANTIBODIES TO CD154 AND METHODS OF THEIR APPLICATION
EA201591380A1 (en) ANTAGONISTS Kv1.3 AND METHODS OF THEIR APPLICATION
MA39347B2 (en) Uti fusion proteins
JOP20140008B1 (en) Use of nicotinic alpha-7 acetylcholine receptor cofactors